<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61454">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305888</url>
  </required_header>
  <id_info>
    <org_study_id>LP0084-1148</org_study_id>
    <nct_id>NCT02305888</nct_id>
  </id_info>
  <brief_title>Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively</brief_title>
  <official_title>Safety of LEO 43204 0.018%, 0.037% and 0.1% for Actinic Keratosis Applied Once Daily for Three Consecutive Days on Face/Chest, Scalp and Trunk/Extremities, Respectively</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to investigate the Safety of LEO 43204 0.018%, 0.037% and 0.1%
      for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and
      trunk/extremities, respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects experiencing DLTs (Dose limiting Toxicities) based on LSRs (Local Skin Reactions)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete clearance of AKs</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in AK count</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>LEO 43204, 0.018% once daily for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 43204, 0.037% once daily for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 43204, 0.1% once daily for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 43204</intervention_name>
    <description>Treatment of actinic keratosis</description>
    <arm_group_label>LEO 43204, 0.018% once daily for 3 days</arm_group_label>
    <arm_group_label>LEO 43204, 0.037% once daily for 3 days</arm_group_label>
    <arm_group_label>LEO 43204, 0.1% once daily for 3 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects with 5 to 20 clinically typical, visible and, discrete, nonhyperkeratotic and
        non-hypertrophic AKs within a selected treatment area of sun-damaged skin on either:

          -  The full face

          -  The full balding scalp

          -  A contiguous area of approximately 250 cm2 on trunk or extremities

        Exclusion Criteria:

        Location of the treatment area (full face, full balding scalp or chest) within 5 cm of an
        incompletely healed wound or within 5 cm of a suspected basal cell carcinoma (BCC) or SCC.

        Previously assigned treatment in this clinical trial or previously participated in a
        clinical trial in the LEO 43204 programme.

        Treatment with ingenol mebutate gel in the selected treatment area within the last 12
        months

        Lesions in the treatment area that have: atypical clinical appearance (e.g. cutaneous
        horns) and/or, recalcitrant disease (e.g., did not respond to cryotherapy on two previous
        occasions).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M Siegel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Long Island Skin Cancer and Dermatologic Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Long Island Skin Cancer and Dermatologic Surgery</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 1, 2016</lastchanged_date>
  <firstreceived_date>December 1, 2014</firstreceived_date>
  <firstreceived_results_disposition_date>August 1, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
